8-K: Moderna Reports Q4 and Fiscal Year 2024 Financial Results, Provides Business Updates, and Submits Three mRNA Products for Regulatory Approval

Moderna announces Q4 revenues of $1.0 billion, a GAAP net loss of $(1.1) billion, and submits three investigational mRNA products for regulatory approval.

Summary

• Moderna reported fourth quarter revenues of $1.0 billion and a GAAP net loss of $(1.1) billion, which includes approximately $0.2 billion of non-cash charges related to manufacturing resizing.
• Full-year revenues were $3.2 billion, with a GAAP net loss of $(3.6) billion.
• The company expects a 2025 revenue range of $1.5 to $2.5 billion and an ending cash balance of approximately $6 billion.
• Moderna submitted three investigational mRNA products for regulatory approval, including its next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccine.
• The company aims to remove nearly $1 billion in costs by the end of 2025.
• Spikevax sales for the full year 2024 were $3.1 billion.
• mRESVIA sales for the full year 2024 were $25 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While Moderna is making progress in its pipeline and cost reduction efforts, the financial results show a significant decline in revenue and a net loss for the year. The forward-looking statements provide some optimism, but the risks and uncertainties associated with the company's pipeline programs temper the overall sentiment.

Positives

• Moderna successfully filed three Biologics License Applications in the final months of the year.
• The company reduced its costs by 27 percent compared to 2023.
• Moderna is entering 2025 with two approved products, Spikevax and mRESVIA.
• Moderna's RSV vaccine has been approved in multiple regions, including the United States, Canada, and the EU.
• The company anticipates multiple approvals starting this year, along with key Phase 3 readouts that will support long-term growth.
• Cash, cash equivalents and investments as of December 31, 2024, were $9.5 billion.

Negatives

• Moderna reported a GAAP net loss of $(1.1) billion for Q4 2024 and $(3.6) billion for the full year.
• Total revenue decreased significantly in both Q4 and the full year compared to the previous year.
• Net product sales decreased by 66% in Q4 2024 compared to Q4 2023.
• The company expects revenue of approximately $0.2 billion in the first half of 2025, reflecting the seasonality of its respiratory business.

Risks

• The forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially.
• The company's reliance on the success of its pipeline programs poses a risk if clinical trials are unsuccessful or regulatory approvals are delayed.
• The transition to a seasonal commercial market for COVID-19 vaccines may result in lower sales volumes.
• The trial for the Norovirus vaccine is currently on FDA clinical hold following a single adverse event report of a case of Guillain-Barr syndrome, which is currently under investigation.
• The Data Safety Monitoring Board (DSMB) met to review the initial study data for the CMV vaccine and has informed the Company that the criterion for early efficacy was not met.

Future Outlook

Moderna expects 2025 revenue to be in the range of $1.5 to $2.5 billion and aims to deliver up to 10 product approvals through 2027. The company also plans to reduce costs by nearly $1 billion by the end of 2025.

Management Comments

• Stphane Bancel, Chief Executive Officer of Moderna, stated that the company made progress in 2024 across its late-stage pipeline and cost reduction efforts.
• Bancel mentioned that the team successfully filed three Biologics License Applications in the final months of the year and reduced costs by 27 percent compared to 2023.
• Bancel noted that in 2025, the company remains focused on driving sales, delivering up to 10 product approvals through 2027, and expanding cost efficiencies across its business.

Industry Context

Moderna's focus on mRNA technology positions it as a key player in the rapidly evolving landscape of vaccine and therapeutic development. The company's progress in respiratory vaccines and oncology therapeutics reflects broader industry trends towards personalized medicine and innovative vaccine platforms.

Comparison to Industry Standards

• Moderna's revenue decline reflects the broader shift in the COVID-19 vaccine market from pandemic-level demand to a seasonal commercial model, similar to what companies like Pfizer and Novavax are experiencing.
• The company's focus on cost reduction aligns with industry-wide efforts to improve efficiency and profitability in a more competitive market.
• Moderna's pipeline of mRNA-based vaccines and therapeutics is comparable to other leading biotechnology companies, such as BioNTech, which are also exploring the potential of mRNA technology in various disease areas.
• The submission of three BLAs in late 2024 demonstrates Moderna's commitment to bringing new products to market, similar to the strategies employed by established pharmaceutical companies like Merck and Johnson & Johnson.

Stakeholder Impact

• Shareholders may be concerned about the decline in revenue and the net loss for the year.
• Employees may be affected by the company's cost reduction efforts.
• Customers may benefit from the potential approval of new vaccines and therapeutics.
• Suppliers may be impacted by changes in the company's manufacturing operations.
• Creditors may be monitoring the company's financial performance and cash position.

Next Steps

• The company will focus on driving sales and delivering up to 10 product approvals through 2027.
• Moderna will continue to expand cost efficiencies across its business and aims to remove nearly $1 billion in costs by the end of 2025.
• The company will await regulatory decisions on its submitted Biologics License Applications for its next-generation COVID vaccine, RSV vaccine, and flu/COVID combination vaccine.
• Moderna will continue its Phase 3 studies for its CMV vaccine and norovirus vaccine.
• The company will start a registrational study for its MMA therapeutic in 2025.

Key Dates

Keywords

Moderna, mRNA, Vaccine, Financial Results, COVID-19, RSV, mRESVIA, Spikevax, Regulatory Approval, Clinical Trials